Orchard Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	112.88	104.24	72.72	110.84
Revenue Growth (YoY)	42.32%	43.35%	-34.39%	-
Cost of Revenue	39.91	37.92	31.07	32.46
Gross Profit	72.97	66.33	41.65	78.38
Selling, General & Admin	13.82	14.47	13.87	13.91
Other Operating Expenses	1.1	0.99	0.94	0.8
Operating Expenses	64.55	62.18	74.83	39.3
Operating Income	8.43	4.14	-33.18	39.08
Interest Expense	-1.51	-0.97	-0.09	-0.02
Interest & Investment Income	0.44	1.07	2	-
Currency Exchange Gain (Loss)	0.02	0.03	-0.01	-
Other Non Operating Income (Expenses)	2.24	3.53	-	-
EBT Excluding Unusual Items	9.62	7.8	-31.28	39.06
Merger & Restructuring Charges	-0.5	-0.4	-0.04	-
Gain (Loss) on Sale of Assets	0.21	-	-	0.34
Asset Writedown	-	-	0.88	-
Pretax Income	9.32	7.4	-30.44	39.4
Income Tax Expense	3.17	2.84	3.36	-
Net Income	6.15	4.56	-33.8	39.4
Net Income to Common	6.15	4.56	-33.8	39.4
Shares Outstanding (Basic)	517	485	308	173
Shares Outstanding (Diluted)	553	522	308	173
Shares Change (YoY)	45.13%	69.49%	77.75%	-
EPS (Basic)	0.01	0.01	-0.11	0.23
EPS (Diluted)	0.01	0.01	-0.11	0.23
Free Cash Flow	-224.24	-161.41	-61.85	59.47
Free Cash Flow Per Share	-0.41	-0.31	-0.20	0.34
Gross Margin	64.65%	63.63%	57.27%	70.71%
Operating Margin	7.47%	3.97%	-45.63%	35.26%
Profit Margin	5.45%	4.37%	-46.48%	35.55%
Free Cash Flow Margin	-198.65%	-154.84%	-85.05%	53.66%
EBITDA	53.47	45.77	13.03	61.45
EBITDA Margin	47.37%	43.91%	17.91%	55.44%
D&A For EBITDA	45.04	41.63	46.21	22.37
EBIT	8.43	4.14	-33.18	39.08
EBIT Margin	7.47%	3.97%	-45.63%	35.26%
Effective Tax Rate	34.01%	38.43%	-	-
Revenue as Reported	112.88	104.24	72.72	110.84

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.